{"title":"The effect of quipazine, a serotonin receptor agonist, on serum corticosterone concentration in rats.","authors":"R W Fuller, H D Snoddy, J A Clemens","doi":"10.3109/07435807809089015","DOIUrl":null,"url":null,"abstract":"<p><p>Quipazine, a serotonin receptor agonist, increased serum corticosterone within 30 min after its i.p. injection (at 10 mg/kg) into rats; the effect persisted at 1 and 2 hrs, but not at 4 hrs. Elevation of serum corticosterone did not occur with a 1.25 mg/kg dose of quipazine but was dose-related over a 2.5-20 mg/kg dose range. The effect of quipazine was completely prevented by methergoline, a serotonin receptor antagonist. The effect of quipazine was present in rats pretreated with 5,7-dihydroxytryptamine to destroy serotonin nerves and was not enhanced (as was the effect of L-5-hydroxytryptophan) by fluoxetine pretreatment. These data are compatible with the idea that quipazine increases serum corticosterone as a consequence of direct stimulation of serotonin receptors in brain.</p>","PeriodicalId":75821,"journal":{"name":"Endocrine research communications","volume":"5 2","pages":"161-71"},"PeriodicalIF":0.0000,"publicationDate":"1978-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/07435807809089015","citationCount":"40","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/07435807809089015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 40
Abstract
Quipazine, a serotonin receptor agonist, increased serum corticosterone within 30 min after its i.p. injection (at 10 mg/kg) into rats; the effect persisted at 1 and 2 hrs, but not at 4 hrs. Elevation of serum corticosterone did not occur with a 1.25 mg/kg dose of quipazine but was dose-related over a 2.5-20 mg/kg dose range. The effect of quipazine was completely prevented by methergoline, a serotonin receptor antagonist. The effect of quipazine was present in rats pretreated with 5,7-dihydroxytryptamine to destroy serotonin nerves and was not enhanced (as was the effect of L-5-hydroxytryptophan) by fluoxetine pretreatment. These data are compatible with the idea that quipazine increases serum corticosterone as a consequence of direct stimulation of serotonin receptors in brain.